Election 2026
Independent, source-first accountability
Issue record
In short
El-Sayed's campaign would expand Medicare to all needed care without premiums, copays or deductibles; Rogers's would fine hospitals and insurers that don't post real prices. Christensen's campaign backs opt-in Medicaid for All; no position by Long was found on the pages checked; Marsh's campaign backs single-payer; no position by Kristy was found on the pages checked. Rogers voted for laws with generic-drug sections; no bill he sponsored names generics in its title.
Campaign positions
He says he will fight to expand Medicare to cover all necessary care, including vision, dental and hearing, for every American without premiums, copays or deductibles, and that he wrote a book on Medicare for All. Until then he opposes privatizing Medicare or cutting Medicaid and the ACA.
His health plan would fine hospitals and insurers that do not post real prices, expand access to TrumpRx and speed approval of lower-cost generic drugs, and force insurers to publicly report denial rates, approval times and appeal outcomes, with penalties for excessive denials.
She proposes Medicaid for All as opt-in coverage for citizens and legal residents, covering all medically necessary care, with premiums capped by income and free below a set threshold, funded by drug price negotiation, administrative savings, spending cuts and closing corporate and wealth tax loopholes.
No campaign website, platform or public statement by him was found. His FEC committee registration lists no website, the U.S. Taxpayers Party of Michigan's candidates page lists no candidates, and a web search for his name with the party and the office returned only election listings.
He says every citizen should have access to quality health services by default and that the best way to ensure it is a single-payer system.
No campaign website, platform or public statement by him was found. The FEC records no campaign committee for him, the Natural Law Party of Michigan's site refused an automated reader and was not read, and a web search for his name with the party and the office returned only election listings and a poll.
Evidence timeline
official action
He cosponsored the House's 2007 FDA bill and voted for the law limiting ways to delay generics, plus 2003 and 2012 bills with generic drug sections; none of his own bills names generics.
In the October 8 WOOD TV8 debate, Rogers said that in Congress he pushed to speed up generic drugs, and that drug companies are not happy about it. No bill he sponsored has "generic" in its title. In 2007 he was an original cosponsor of the House's FDA bill (H.R. 2900) and voted for it and for the final bill, H.R. 3580 (Roll Calls 617 and 885). That law, Public Law 110-85, bars a drug's maker from using its required safety restrictions to block or delay a generic, and limits how far petitions can delay a generic's approval. He was an original cosponsor of the Pathway for Biosimilars Act in 2008 and 2009 (H.R. 5629 and H.R. 1548), which would have set up a way to approve copies of biologic drugs, but not until 12 years after the original was licensed; neither left committee. He voted for the 2003 Medicare law (Roll Call 669), whose title XI, "Access to Affordable Pharmaceuticals", changed the rules for generic drug applications. In 2012 he voted for the House's FDA bill (H.R. 5651, Roll Call 294), which set fees on generic drug applications, including a one-time fee on the backlog, to pay for the FDA's generic drug work; those fees became law that year in the final bill, S. 3187 (Public Law 112-144). A biosimilar approval route with the same 12-year wait became law in 2010 in the Affordable Care Act, which he voted against (Roll Call 165). Limit: "Pushed" is his word. The record shows his cosponsorships and votes, not what he did behind the scenes, and each of these laws did much more than generic drugs.
See something wrong or incomplete? Report it for review.
Abdul for U.S. Senate · Reviewed Sep 23, 2026
Campaign-controlled source. Positions are attributed, not independently verified facts. Covers health care, veterans, drug prices and public health.
candidate statement
For: Abdul El-Sayed: campaign position
Rogers for Senate · Reviewed Sep 23, 2026
Campaign-controlled source. Positions are attributed, not independently verified facts.
candidate statement
For: Mike Rogers: campaign position
Lydia Christensen for U.S. Senate · Reviewed Sep 23, 2026
Campaign-controlled source. Positions are attributed, not independently verified facts. Fifty-two issue entries in eleven categories, rendered in the browser from the site's own data file (https://www.lydialynnchristensen.com/get_issues.php), which is what the quote checks read. The page says its policies are living documents that she updates.
candidate statement
For: Lydia Christensen: campaign position
Federal Election Commission · Reviewed Sep 23, 2026
Principal campaign committee for candidate S6MI00566 ("LONG, TIMOTHY E", U.S. Taxpayers Party). Its only filing is a Statement of Organization received July 27, 2026, which lists no website. It has filed no financial report.
fec filing
For: Tim Long: campaign position
U.S. Taxpayers Party of Michigan · Reviewed Sep 23, 2026
The party's candidates page, read in a browser on 2026-09-23 because the site is built in the browser. It read "No candidates have been added yet."
endorsement
For: Tim Long: campaign position
Committee to Elect Douglas P. Marsh · Reviewed Sep 23, 2026
Campaign-controlled source. Positions are attributed, not independently verified facts. A one-page site whose domain matches the website his committee filed with the FEC. It sets out five priorities and links no social account.
candidate statement
For: Douglas P. Marsh: campaign position
Federal Election Commission · Reviewed Sep 23, 2026
The FEC's candidate record, party Natural Law Party. OpenFEC lists no committee of any designation for this candidate and no filing under his candidate ID.
fec filing
For: Walter P. Kristy: campaign position
Natural Law Party of Michigan · Reviewed Sep 23, 2026
The party's site. On 2026-09-23 it answered with a Cloudflare challenge page (HTTP 403) and was not read.
endorsement
For: Walter P. Kristy: campaign position
WOOD TV8 · Published Oct 8, 2026 · Reviewed Oct 10, 2026
15:34. Paraphrased from YouTube's captions of the station's video; no second transcript was found to confirm the exact words.
candidate statement
For: Mike Rogers: Matches stated direction
Congress.gov · Reviewed Oct 10, 2026
All 129 bills, resolutions and amendments he sponsored, read from the Congress.gov API on October 10, 2026. None has "generic" in its title; his 23 amendments carry no title.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Published Jun 28, 2007 · Reviewed Oct 10, 2026
Text as introduced, naming Mr. Rogers of Michigan among the original cosponsors. It would bar using a drug's required safety restrictions to block or delay approval of a generic (section 505(j)) application.
official legislative record
For: Mike Rogers: Matches stated direction
Office of the Clerk, U.S. House of Representatives · Published Jul 11, 2007 · Reviewed Oct 10, 2026
Recorded vote of July 11, 2007 (403 to 16), read from the Clerk's roll-call XML by member ID R000572.
official legislative record
For: Mike Rogers: Matches stated direction
Office of the Clerk, U.S. House of Representatives · Published Sep 19, 2007 · Reviewed Oct 10, 2026
Recorded vote of September 19, 2007 (405 to 7), read from the Clerk's roll-call XML by member ID R000572.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Published Sep 27, 2007 · Reviewed Oct 10, 2026
Enacted text of H.R. 3580, signed September 27, 2007. Section 901 bars using a drug's required safety restrictions to block or delay a generic application; section 914 limits delays to generic approvals from citizen petitions.
official legislative record
For: Mike Rogers: Matches stated direction
Congress.gov · Published Mar 13, 2008 · Reviewed Oct 10, 2026
Sponsored by Anna Eshoo; he was an original cosponsor. Last action: referred to a Judiciary subcommittee on April 14, 2008.
official legislative record
For: Mike Rogers: Matches stated direction
Congress.gov · Published Mar 17, 2009 · Reviewed Oct 10, 2026
Sponsored by Anna Eshoo; he was an original cosponsor. The summary says approval of a copy could not take effect until 12 years after the original was first licensed. Last action: referred to the Subcommittee on Health on March 18, 2009.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Reviewed Sep 23, 2026
Enacted text. It adds a new "Part D--Voluntary Prescription Drug Benefit Program" to Medicare. Title XI, "Access to Affordable Pharmaceuticals", changes the rules for generic drug applications.
official legislative record
For: Mike Rogers: Matches stated direction
Office of the Clerk, U.S. House of Representatives · Reviewed Sep 23, 2026
Recorded vote of November 22, 2003 (220 to 215), read from the Clerk's roll-call XML by member ID R000572.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Published May 30, 2012 · Reviewed Oct 10, 2026
Text as passed by the House. Title III, the Generic Drug User Fee Amendments of 2012, sets FDA fees on generic drug applications, including a one-time fee on applications pending on October 1, 2012.
official legislative record
For: Mike Rogers: Matches stated direction
Office of the Clerk, U.S. House of Representatives · Published May 30, 2012 · Reviewed Oct 10, 2026
Recorded vote of May 30, 2012 (387 to 5), read from the Clerk's roll-call XML by member ID R000572.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Published Jul 9, 2012 · Reviewed Oct 10, 2026
Enacted text of S. 3187, signed July 9, 2012. Title III is the Generic Drug User Fee Amendments of 2012. The House passed this version by voice vote.
official legislative record
For: Mike Rogers: Matches stated direction
U.S. Government Publishing Office · Reviewed Sep 23, 2026
Enacted text. Title III, subtitle B is headed "Improving Medicare for Patients and Providers". Section 7002 sets up an approval pathway for biosimilar biological products, effective no sooner than 12 years after the original was first licensed.
official legislative record
For: Mike Rogers: Matches stated direction
Office of the Clerk, U.S. House of Representatives · Reviewed Sep 23, 2026
Recorded vote of March 21, 2010, on the Patient Protection and Affordable Care Act, read from the Clerk's roll-call XML by member ID R000572.
official legislative record
For: Mike Rogers: Matches stated direction